AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...
Novo Nordisk (NVO) closed the most recent trading day at $47.81, moving -2.35% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%. Meanwhile, the ...
4h
Federal judges consolidate GLP-1 vision loss lawsuits, sends cases to federal judge in Pennsylvania
Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...
On December 15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...
GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.
Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is undertaking a Phase 3 clinical study ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...
For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...
ENV-308 is a first-in-class, once-daily oral therapy designed for chronic weight management, emphasizing high-quality weight loss with muscle mass preservation and durable long-term maintenancePhase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback